Invasive Decoding and Stimulation of Altered Reward Computations in Depression
Novel invasive neurostimulation stimulation strategies through neurosurgical interventions are emerging as a promising therapeutical strategy for major depressive disorder. These have been applied mostly to the anterior cingulate cortex, but other limbic brain regions h...
Age: 18 - 80 years
Gender: All
The Effects of a Music Therapy Respiratory Protocol on Post-Covid-19 Respiratory Symptoms
The effects of a tested and published music therapy respiratory protocol shown to be
efficacious with pediatric asthma and adult COPD is being studied with individuals living
with post-Covid-19 respiratory symptoms. An interventional, single arm study is being
con...
Age: 18 years - 66+
Gender: All
Targeting IL-17A for Treatment-Resistant Depression
The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).
Age: 18 - 65 years
Gender: All
XEN1101 for Major Depressive Disorder
This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener XEN1101 (Xenon Pharmaceuticals).
Age: 18 - 65 years
Gender: All
A Depression and Opioid Pragmatic Trial in Pharmacogenetics (DCRI Coordinating Center)
This study is comprised of three separate pharmacogenetic trials grouped into a single
protocol due to similarities in the intervention, the hypotheses, and the trial design. The
three trials are the Acute Pain Trial, the Chronic Pain Trial, and the Depression Trial...
Age: 8 years - 66+
Gender: All
Real-time Biofeedback With 7-Tesla MRI for Treatment of Depression
Previous research has shown that modulation of a brain region in rodents, the ventral
tegmental area (VTA), improves depressive symptoms. Human research has also shown that VTA
self-modulation using 'biofeedback' is feasible and successful in healthy volunteers. Thi...
Age: 18 - 65 years
Gender: All
DBS for TRD With the Medtronic Summit RC+S
Of the estimated 30 million Americans who suffer from Major Depressive Disorder, approximately 10% are considered treatment resistant. Deep brain stimulation (DBS) to a region of the brain called the subcallosal cingulate (SCC) is an emerging strategy for treatment resi...
Age: 25 - 70 years
Gender: All
The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment
To investigate the impact of a long-term light treatment intervention on sleep physiology and
memory in mild cognitively impaired and mild Alzheimer's disease patients living at home. The
goal is also to measure the impact of the lighting intervention on caregivers'...
Age: 50 years - 66+
Gender: All
The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment
To investigate the impact of a long-term light treatment intervention on sleep physiology and memory in mild cognitively impaired and mild Alzheimer's disease patients living at home. The goal is also to measure the impact of the lighting intervention on caregivers' sle...
Age: 50 years - 66+
Gender: All
Neuraxial Preservative Free Morphine for Normal Spontaneous Vaginal Delivery
Patients presenting for normal spontaneous vaginal delivery who have a neuraxial anesthestic
will be randomized to receive preservative free morphine or saline placebo after delivery.
Age: 18 years - 66+
Gender: Female
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Objectives of this study are to determine whether active VNS Therapy treatment is superior to
a no stimulation control in producing a reduction in baseline depressive symptom severity,
based on multiple depression scale assessment tools at 12 months from randomizati...
Age: 18 years - 66+
Gender: All
Telemedicine in Age-Related Macular Degeneration (AMD)
AMD affects 15 million Americans, with 200,000 new advanced cases diagnosed each year. AMD is the leading cause of blindness in this country, from either the “dry” or “wet” advanced forms. At present, there is no treatment for dry AMD. Besides bl...
Age: 50 - 90 years
Gender: All
Light and the Effect on Metabolic Syndrome and Alzheimer's Disease
This study's main hypothesis is that a delivering a tailored lighting intervention (TLI) will
provide a successful means for promoting circadian entrainment and treating metabolic disease
and inflammation in patients with mild cognitive impairment (MCI) and Alzheime...
Age: 55 years - 66+
Gender: All
ToRsemide compArisoN with furoSemide FOR Management of Heart Failure (TRANSFORM-HF)
An approximately 6000-patient, randomized, unblinded, two-arm, multicenter clinical trial comparing torsemide with furosemide among patients hospitalized for heart failure. 1:1 randomization to either oral torsemide OR oral furosemide (dosing at discretion of local pr...
Age: 18 - 85 years
Gender: All
Systematic Light Exposure for Fatigue in Breast Cancer Patients
Cancer related fatigue (CRF) is a stressful and constant tiredness related to cancer and/or
its treatment. CRF is the most intense during treatment and can severely interfere with
activities of daily living, such as tasks that require physical strength or thinking c...
Age: 18 years - 66+
Gender: Female
ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
The goal of the study is to conduct a comparative randomized trial of electroconvulsive
therapy (ECT) vs. ketamine for patients with treatment resistant depression (TRD) in a real
world setting with patient reported outcomes as primary and secondary outcome measures...
Age: 21 - 75 years
Gender: All
Methodology Issues in a Tailored Light Treatment for Persons With Dementia
Tailored light treatment will increase sleep efficiency, reduce depression and reduce
agitation scores in those with Alzheimer's disease and related dementia
Age: 65 years - 66+
Gender: All